tiprankstipranks
Regeneron (REGN)
NASDAQ:REGN
US Market
REGN
Regeneron
RESEARCH TOOLSreports
Want to see REGN full AI Analyst Report?

Regeneron (REGN) Stock Forecast & Price Target

5,186 Followers
See the Price Targets and Ratings of:

REGN Analyst Ratings

Strong Buy
21Ratings
Strong Buy
16 Buy
5 Hold
0 Sell
Based on 21 analysts giving stock ratings to
Regeneron
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

REGN Stock 12 Month Forecast

Average Price Target

$877.80
▲(16.95% Upside)
Based on 21 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is $877.80 with a high forecast of $1,057.00 and a low forecast of $742.00. The average price target represents a 16.95% change from the last price of $750.57.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"487":"$487","1058":"$1,058","629.75":"$629.8","772.5":"$772.5","915.25":"$915.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1057,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.06K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":877.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$877.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":742,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$742.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[487,629.75,772.5,915.25,1058],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,701.42,728.7723076923077,756.1246153846154,783.4769230769231,810.8292307692308,838.1815384615385,865.5338461538461,892.8861538461538,920.2384615384615,947.5907692307692,974.9430769230769,1002.2953846153846,1029.6476923076923,{"y":1057,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,701.42,714.9876923076922,728.5553846153846,742.1230769230768,755.6907692307692,769.2584615384615,782.8261538461538,796.3938461538461,809.9615384615385,823.5292307692307,837.0969230769231,850.6646153846153,864.2323076923076,{"y":877.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,701.42,704.5415384615384,707.6630769230769,710.7846153846153,713.9061538461539,717.0276923076923,720.1492307692307,723.2707692307692,726.3923076923077,729.5138461538461,732.6353846153846,735.756923076923,738.8784615384616,{"y":742,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":586.793,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":488.864,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":532.789,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":556.654,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":579.276,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":598.468,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":650.201,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":749.208,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":770.942,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":754.112,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":790.81,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":777.25,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":701.42,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,057Average Price Target$877.80Lowest Price Target$742.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on REGN
Geoff Meacham
Citi
Citi
$900
Buy
19.91%
Upside
Reiterated
05/01/26
Citi Reaffirms Their Buy Rating on Regeneron (REGN)
Guggenheim Analyst forecast on REGN
Yatin Suneja
Guggenheim
Guggenheim
$975→$995
Buy
32.57%
Upside
Reiterated
04/30/26
Regeneron price target raised to $995 from $975 at GuggenheimRegeneron price target raised to $995 from $975 at Guggenheim
Evercore ISI Analyst forecast on REGN
Cory Kasimov
Evercore ISI
Evercore ISI
$875
Buy
16.58%
Upside
Reiterated
04/30/26
Analysts Conflicted on These Healthcare Names: Teladoc (NYSE: TDOC), Spyre Therapeutics (NASDAQ: SYRE) and Regeneron (NASDAQ: REGN)
Truist Financial Analyst forecast on REGN
Gregory Renza
Truist Financial
Truist Financial
$801→$796
Buy
6.05%
Upside
Reiterated
04/30/26
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Regeneron (REGN)
Morgan Stanley Analyst forecast on REGN
Terence Flynn
Morgan Stanley
Morgan Stanley
$796→$788
Hold
4.99%
Upside
Reiterated
04/30/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Universal Health (NYSE: UHS), Viking Therapeutics (NASDAQ: VKTX) and Regeneron (NASDAQ: REGN)
Oppenheimer Analyst forecast on REGN
Matthew Biegler
Oppenheimer
Oppenheimer
$865
Buy
15.25%
Upside
Reiterated
04/30/26
Analysts Are Bullish on These Healthcare Stocks: Universal Health (UHS), Glaukos (GKOS)
Scotiabank Analyst forecast on REGN
Louise Chen
Scotiabank
Scotiabank
$770
Hold
2.59%
Upside
Reiterated
04/30/26
Scotiabank Sticks to Its Hold Rating for Regeneron (REGN)
Bank of America Securities Analyst forecast on REGN
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
04/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (NASDAQ: REGN), Bausch + Lomb Corporation (NYSE: BLCO) and Indivior (NASDAQ: INDV)
Barclays Analyst forecast on REGN
Eliana Merle
Barclays
Barclays
$923→$917
Buy
22.17%
Upside
Reiterated
04/30/26
Regeneron (REGN) Gets a Buy from Barclays
Canaccord Genuity Analyst forecast on REGN
John Newman
Canaccord Genuity
Canaccord Genuity
$1,057
Buy
40.83%
Upside
Reiterated
04/30/26
Canaccord Genuity Reaffirms Their Buy Rating on Regeneron (REGN)
RBC Capital Analyst forecast on REGN
Brian Abrahams
RBC Capital
RBC Capital
$779→$762
Hold
1.52%
Upside
Reiterated
04/29/26
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (NYSE: BHC), Spyre Therapeutics (NASDAQ: SYRE) and Regeneron (NASDAQ: REGN)
Goldman Sachs Analyst forecast on REGN
Salveen Richter
Goldman Sachs
Goldman Sachs
$967→$968
Buy
28.97%
Upside
Assigned
04/29/26
Regeneron: Earnings Strength and Pipeline Optionality Support Buy Rating as 12-Month Price Target Ticks Up to $968
BMO Capital Analyst forecast on REGN
Evan Seigerman
BMO Capital
BMO Capital
$900
Buy
19.91%
Upside
Reiterated
04/29/26
Regeneron: Buy Rating Reiterated as Analyst Sees Melanoma Trial Sell-Off Overdone; $900 Price Target Unchanged
Cantor Fitzgerald Analyst forecast on REGN
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$800
Buy
6.59%
Upside
Reiterated
04/29/26
Cantor Fitzgerald Sticks to Its Buy Rating for Regeneron (REGN)
Piper Sandler Analyst forecast on REGN
Biren Amin
Piper Sandler
Piper Sandler
$875
Buy
16.58%
Upside
Reiterated
04/24/26
Analysts' Top Healthcare Picks: AbbVie (ABBV), Regeneron (REGN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on REGN
Geoff Meacham
Citi
Citi
$900
Buy
19.91%
Upside
Reiterated
05/01/26
Citi Reaffirms Their Buy Rating on Regeneron (REGN)
Guggenheim Analyst forecast on REGN
Yatin Suneja
Guggenheim
Guggenheim
$975→$995
Buy
32.57%
Upside
Reiterated
04/30/26
Regeneron price target raised to $995 from $975 at GuggenheimRegeneron price target raised to $995 from $975 at Guggenheim
Evercore ISI Analyst forecast on REGN
Cory Kasimov
Evercore ISI
Evercore ISI
$875
Buy
16.58%
Upside
Reiterated
04/30/26
Analysts Conflicted on These Healthcare Names: Teladoc (NYSE: TDOC), Spyre Therapeutics (NASDAQ: SYRE) and Regeneron (NASDAQ: REGN)
Truist Financial Analyst forecast on REGN
Gregory Renza
Truist Financial
Truist Financial
$801→$796
Buy
6.05%
Upside
Reiterated
04/30/26
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Regeneron (REGN)
Morgan Stanley Analyst forecast on REGN
Terence Flynn
Morgan Stanley
Morgan Stanley
$796→$788
Hold
4.99%
Upside
Reiterated
04/30/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Universal Health (NYSE: UHS), Viking Therapeutics (NASDAQ: VKTX) and Regeneron (NASDAQ: REGN)
Oppenheimer Analyst forecast on REGN
Matthew Biegler
Oppenheimer
Oppenheimer
$865
Buy
15.25%
Upside
Reiterated
04/30/26
Analysts Are Bullish on These Healthcare Stocks: Universal Health (UHS), Glaukos (GKOS)
Scotiabank Analyst forecast on REGN
Louise Chen
Scotiabank
Scotiabank
$770
Hold
2.59%
Upside
Reiterated
04/30/26
Scotiabank Sticks to Its Hold Rating for Regeneron (REGN)
Bank of America Securities Analyst forecast on REGN
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
04/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (NASDAQ: REGN), Bausch + Lomb Corporation (NYSE: BLCO) and Indivior (NASDAQ: INDV)
Barclays Analyst forecast on REGN
Eliana Merle
Barclays
Barclays
$923→$917
Buy
22.17%
Upside
Reiterated
04/30/26
Regeneron (REGN) Gets a Buy from Barclays
Canaccord Genuity Analyst forecast on REGN
John Newman
Canaccord Genuity
Canaccord Genuity
$1,057
Buy
40.83%
Upside
Reiterated
04/30/26
Canaccord Genuity Reaffirms Their Buy Rating on Regeneron (REGN)
RBC Capital Analyst forecast on REGN
Brian Abrahams
RBC Capital
RBC Capital
$779→$762
Hold
1.52%
Upside
Reiterated
04/29/26
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (NYSE: BHC), Spyre Therapeutics (NASDAQ: SYRE) and Regeneron (NASDAQ: REGN)
Goldman Sachs Analyst forecast on REGN
Salveen Richter
Goldman Sachs
Goldman Sachs
$967→$968
Buy
28.97%
Upside
Assigned
04/29/26
Regeneron: Earnings Strength and Pipeline Optionality Support Buy Rating as 12-Month Price Target Ticks Up to $968
BMO Capital Analyst forecast on REGN
Evan Seigerman
BMO Capital
BMO Capital
$900
Buy
19.91%
Upside
Reiterated
04/29/26
Regeneron: Buy Rating Reiterated as Analyst Sees Melanoma Trial Sell-Off Overdone; $900 Price Target Unchanged
Cantor Fitzgerald Analyst forecast on REGN
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$800
Buy
6.59%
Upside
Reiterated
04/29/26
Cantor Fitzgerald Sticks to Its Buy Rating for Regeneron (REGN)
Piper Sandler Analyst forecast on REGN
Biren Amin
Piper Sandler
Piper Sandler
$875
Buy
16.58%
Upside
Reiterated
04/24/26
Analysts' Top Healthcare Picks: AbbVie (ABBV), Regeneron (REGN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

3 Months
xxx
Success Rate
15/26 ratings generated profit
58%
Average Return
+3.60%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 57.69% of your transactions generating a profit, with an average return of +3.60% per trade.
1 Year
David RisingerLeerink Partners
Success Rate
20/26 ratings generated profit
77%
Average Return
+15.99%
Copying David Risinger's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +15.99% per trade.
2 Years
xxx
Success Rate
19/26 ratings generated profit
73%
Average Return
+16.13%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 73.08% of your transactions generating a profit, with an average return of +16.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REGN Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
0
0
Buy
41
42
41
43
30
Hold
16
16
15
17
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
57
58
56
60
42
In the current month, REGN has received 30 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. REGN average Analyst price target in the past 3 months is 877.80.
Each month's total comprises the sum of three months' worth of ratings.

REGN Financial Forecast

REGN Earnings Forecast

Next quarter’s earnings estimate for REGN is $10.88 with a range of $8.27 to $13.25. The previous quarter’s EPS was $9.47. REGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.
Next quarter’s earnings estimate for REGN is $10.88 with a range of $8.27 to $13.25. The previous quarter’s EPS was $9.47. REGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.

REGN Sales Forecast

Next quarter’s sales forecast for REGN is $3.82B with a range of $3.54B to $4.19B. The previous quarter’s sales results were $3.61B. REGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.
Next quarter’s sales forecast for REGN is $3.82B with a range of $3.54B to $4.19B. The previous quarter’s sales results were $3.61B. REGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.

REGN Stock Forecast FAQ

What is REGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Regeneron’s 12-month average price target is 877.80.
    What is REGN’s upside potential, based on the analysts’ average price target?
    Regeneron has 16.95% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is REGN a Buy, Sell or Hold?
          Regeneron has a consensus rating of Strong Buy which is based on 16 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Regeneron’s price target?
            The average price target for Regeneron is 877.80. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $1,057.00 ,the lowest forecast is $742.00. The average price target represents 16.95% Increase from the current price of $750.57.
              What do analysts say about Regeneron?
              Regeneron’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
                How can I buy shares of REGN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.